ArticleBiophysical journal2009
Specific interactions of clausin, a new lantibiotic, with lipid precursors of the bacterial cell wall.
Article in Biophysical journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Review
- Viability Preservation of Probiotic Bacteria Encapsulated in Pectin-Reinforced pH-Responsive Composite Alginate Hydrogel Matrix as the Synbiotic Delivery System.Probiotics and antimicrobial proteins · 2026Article
- Article
- Secondary Metabolites fromCurrent research in microbial sciences · 2025Review
- Identification and characterisation of antimicrobial compound produced by probiotic Alkalihalobacillus clausii 088AE.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Use of the mCherry fluorescent protein to optimize the expression of class I lanthipeptides in Escherichia coli.Microbial cell factories · 2023Article
- Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment forAntibiotics (Basel, Switzerland) · 2023Review
- Immunomodulatory and Antioxidant Properties of a Novel Potential ProbioticMicroorganisms · 2023Article
- Bacillus clausii for Gastrointestinal Disorders: A Narrative Literature Review.Advances in therapy · 2022Review
- Current Progress and Future Perspectives on the Use of Bacillus clausiiMicroorganisms · 2022Review
- AntimicrobialAntibiotics (Basel, Switzerland) · 2022Review
- Therapeutic efficacy of probioticHeliyon · 2021Article
- Targeting the Achilles' Heel of Bacteria: Different Mechanisms To Break Down the Peptidoglycan Cell Wall during Bacterial Warfare.Journal of bacteriology · 2021Review
- The bacterial cell division protein fragmentThe Journal of biological chemistry · 2020Article
- Survival and Germination ofFrontiers in microbiology · 2020Article
- Molecular Recognition of Lipid II by Lantibiotics: Synthesis and Conformational Studies of Analogues of Nisin and Mutacin Rings A and B.The Journal of organic chemistry · 2019Article
- Bacterial Lipid II Analogs: Novel In Vitro Substrates for Mammalian Oligosaccharyl Diphosphodolichol Diphosphatase (DLODP) Activities.Molecules (Basel, Switzerland) · 2019Article
- Identification of Putative Novel Class-I Lanthipeptides in Firmicutes: A CombinatorialInternational journal of molecular sciences · 2018Article
- Identification and classification of known and putative antimicrobial compounds produced by a wide variety of Bacillales species.BMC genomics · 2016Article
- Efficacy of Lantibiotic Treatment of Staphylococcus aureus-Induced Skin Infections, Monitored by In Vivo Bioluminescent Imaging.Antimicrobial agents and chemotherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the specificity of interaction of a new type A lantibiotic, clausin, isolated from Bacillus clausii, with lipid intermediates of bacterial envelope biosynthesis pathways. Isothermal calorimetry and steady-state fluorescence anisotropy (with dansylated derivatives) identified peptidoglycan lipids I and II, embedded in dodecylphosphocholine micelles, as potential targets. Complex formation with dissociation constants of approximately 0.3 muM and stoichiometry of approximately 2:1 peptides/lipid intermediate was observed. The interaction is enthalpy-driven. For the first time, to our knowledge, we evidenced the interaction between a lantibiotic and C(55)-PP-GlcNAc, a lipid intermediate in the biosynthesis of other bacterial cell wall polymers, including teichoic acids. The pyrophosphate moiety of these lipid intermediates was crucial for the interaction because a strong binding with undecaprenyl pyrophosphate, accounting for 80% of the free energy of binding, was observed. No binding occurred with the undecaprenyl phosphate derivative. The pentapeptide and the N-acetylated sugar moieties strengthened the interaction, but their contributions were weaker than that of the pyrophosphate group. The lantibiotic decreased the mobility of the pentapeptide. Clausin did not interact with the water-soluble UDP-MurNAc- and pyrophosphoryl-MurNAc-pentapeptides, pointing out the importance of the hydrocarbon chain of the lipid target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.